{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:43:21Z","timestamp":1792511001304,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006579","name":"Ministry of Industry and Information Technology of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006579","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.ejmech.2026.119431","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:06:11Z","timestamp":1792166771000},"page":"119431","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["Identification of selective FGFR2\/4 degraders with potent antiproliferative activity"],"prefix":"10.1016","volume":"321","author":[{"given":"Jingyu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunwan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanjie","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0870-3782","authenticated-orcid":false,"given":"Dongfeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119431_bib1","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3390\/cells8060614","article-title":"Fibroblast growth factor receptors (FGFRs): structures and small molecule inhibitors","volume":"8","author":"Dai","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2026.119431_bib2","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.3390\/ijms22126342","article-title":"All good things must end: termination of receptor tyrosine kinase signal","volume":"22","author":"Margiotta","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119431_bib3","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119431_bib4","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41416-020-01157-0","article-title":"Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance","volume":"124","author":"Krook","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.119431_bib5","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signaling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.119431_bib6","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-19-2035","article-title":"Facts and new hopes on selective FGFR inhibitors in solid tumors","volume":"26","author":"Facchinetti","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119431_bib7","article-title":"Advances of fibroblast growth factor\/receptor signaling pathway in hepatocellular carcinoma and its pharmacotherapeutic targets","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119431_bib8","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/jso.23153","article-title":"The correlations between the expression of FGFR4 protein and clinicopathological parameters as well as prognosis of gastric cancer patients","volume":"106","author":"Ye","year":"2012","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.ejmech.2026.119431_bib9","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.3892\/or.2013.2796","article-title":"Combination of the FGFR4 inhibitor PD173074 and 5\u2013Fluorouracil reduces proliferation and promotes apoptosis in gastric cancer","volume":"30","author":"Ye","year":"2013","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejmech.2026.119431_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104567","article-title":"The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder","volume":"151","author":"Roskoski","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2026.119431_bib11","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40265-019-01142-9","article-title":"Erdafitinib: first global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.119431_bib12","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s40265-020-01330-y","article-title":"Pemigatinib: first approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.119431_bib13","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1021\/jm2006222","article-title":"Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase","volume":"54","author":"Guagnano","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119431_bib14","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s40265-021-01567-1","article-title":"Infigratinib: first approval","volume":"81","author":"Kang","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.119431_bib15","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s40265-022-01806-z","article-title":"Futibatinib: first approval","volume":"82","author":"Syed","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.119431_bib16","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.1158\/0008-5472.CAN-19-2568","article-title":"Futibatinib is a novel irreversible FGFR1-4 inhibitor that shows selective antitumor activity against FGFR-Deregulated tumors","volume":"80","author":"Sootome","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119431_bib17","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/cmdc.201800719","article-title":"TAS-120 cancer target binding: defining reactivity and revealing the first fibroblast growth factor receptor 1 (FGFR1) irreversible structure","volume":"14","author":"Kalyukina","year":"2019","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2026.119431_bib18","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1158\/1535-7163.MCT-16-0261","article-title":"E7090, a novel selective inhibitor of fibroblast growth factor receptors, displays potent antitumor activity and prolongs survival in preclinical models","volume":"15","author":"Watanabe Miyano","year":"2016","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.119431_bib19","doi-asserted-by":"crossref","first-page":"12542","DOI":"10.1021\/acs.jmedchem.0c01019","article-title":"Discovery of roblitinib (FGF401) as a reversible-covalent inhibitor of the kinase activity of fibroblast growth factor receptor 4","volume":"63","author":"Fairhurst","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119431_bib20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13046-022-02383-5","article-title":"A first-in-human phase 1\/2 Study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors","volume":"41","author":"Chan","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119431_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115947","article-title":"Insight into the design of FGFR4 selective inhibitors in cancer therapy: prospects and challenges","volume":"263","author":"Chen","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119431_bib22","doi-asserted-by":"crossref","first-page":"S611","DOI":"10.1016\/j.annonc.2023.09.2969","article-title":"1012P first-in-human study of ABSK-011, a novel, highly selective fibroblast growth factor receptor (FGFR) 4 inhibitor for treating advanced hepatocellular carcinoma (HCC) with FGF19 overexpression","volume":"34","author":"Cheng","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2026.119431_bib23","series-title":"FGFR4 Inhibitor, Preparation Method Therefor and Pharmaceutical Use Thereof","year":"2018"},{"key":"10.1016\/j.ejmech.2026.119431_bib24","doi-asserted-by":"crossref","first-page":"6999","DOI":"10.1158\/0008-5472.CAN-17-1865","article-title":"H3B-6527 is a potent and selective inhibitor of FGFR4 in FGF19-driven hepatocellular carcinoma","volume":"77","author":"Joshi","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119431_bib25","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2317756121","article-title":"Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2","volume":"121","author":"Sch\u00f6nherr","year":"2024","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2026.119431_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202100270","article-title":"Recent developments in PROTAC-Mediated protein degradation: from bench to Clinic","volume":"23","author":"Hu","year":"2022","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2026.119431_bib27","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1039\/D2CS00220E","article-title":"Chemistries of bifunctional PROTAC degraders","volume":"51","author":"Cao","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2026.119431_bib28","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1021\/acs.jmedchem.3c01781","article-title":"PROTACs targeting BRM (SMARCA2) afford selective in vivo degradation over BRG1 (SMARCA4) and are active in BRG1 mutant xenograft tumor models","volume":"67","author":"Berlin","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119431_bib29","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.chembiol.2017.09.010","article-title":"Lessons in PROTAC design from selective degradation with a promiscuous warhead","volume":"25","author":"Bondeson","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119431_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112186","article-title":"Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low On-target platelet toxicity","volume":"192","author":"Zhang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119431_bib31","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.apsb.2020.11.009","article-title":"Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation","volume":"11","author":"Jiang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2026.119431_bib32","doi-asserted-by":"crossref","first-page":"8567","DOI":"10.1021\/acs.jmedchem.0c00967","article-title":"Global PROTAC toolbox for degrading BCR-ABL overcomes drug-resistant mutants and adverse effects","volume":"63","author":"Yang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119431_bib33","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1021\/acschembio.3c00548","article-title":"Selective and potent PROTAC degraders of c-Src kinase","volume":"19","author":"Mao","year":"2024","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119431_bib34","doi-asserted-by":"crossref","first-page":"20464","DOI":"10.1021\/acs.jmedchem.5c01640","article-title":"Translational research on the oral delivery of the cytotoxic PROTAC molecule via tumor-targeting prodrug strategy for triple-negative breast cancer treatment","volume":"68","author":"Hu","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119431_bib35","doi-asserted-by":"crossref","first-page":"7560","DOI":"10.1021\/acs.jmedchem.5c00027","article-title":"Discovery of a highly potent and selective tyrosine kinase 2 (TYK2) degrader with in vivo therapeutic efficacy in a murine psoriasis model","volume":"68","author":"Xiong","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119431_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115974","article-title":"Discovery of LWY713 as a potent and selective FLT3 PROTAC degrader with in vivo activity against acute myeloid leukemia","volume":"264","author":"Liu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119431_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217668","article-title":"Selective degradation of FGFR1\/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1\/2 alterations","volume":"619","author":"Uemoto","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2026.119431_bib38","doi-asserted-by":"crossref","first-page":"7438","DOI":"10.1021\/acs.jmedchem.3c00150","article-title":"Discovery of a selective and orally bioavailable FGFR2 degrader for treating gastric cancer","volume":"66","author":"Ma","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119431_bib39","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1158\/1535-7163.MCT-23-0719","article-title":"A selective FGFR1\/2 PROTAC degrader with antitumor activity","volume":"23","author":"Kong","year":"2024","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.119431_bib40","doi-asserted-by":"crossref","first-page":"15905","DOI":"10.1002\/anie.202101328","article-title":"Discovery of a potent degrader for fibroblast growth factor receptor 1\/2","volume":"60","author":"Du","year":"2021","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2026.119431_bib41","doi-asserted-by":"crossref","first-page":"13858","DOI":"10.1021\/acs.jmedchem.5c00731","article-title":"LC-MF-4, a novel FGFR3 degrader for therapeutic intervention in FGFR3-altered cancers","volume":"68","author":"Zheng","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119431_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116780","article-title":"Synthesis and identification of a selective FGFR2 degrader with potent antiproliferative effects in gastric cancer","volume":"277","author":"Feng","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119431_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116612","article-title":"Design, synthesis and antitumor activity of a novel FGFR2-selective degrader to overcome resistance of the FGFR2V564F gatekeeper mutation based on a Pan-FGFR inhibitor","volume":"275","author":"Hu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119431_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128982","article-title":"Development of selective FGFR1 degraders using a rapid synthesis of proteolysis targeting chimera (Rapid-TAC) platform","volume":"75","author":"Guo","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119431_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.108109","article-title":"Design, synthesis, and biological evaluation of novel FGFR1 PROTACs","volume":"155","author":"Wang","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119431_bib46","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3762\/bjoc.22.44","article-title":"Design and synthesis of an erdafitinib-based selective FGFR2 degrader","volume":"22","author":"Jin","year":"2026","journal-title":"Beilstein J. Org. Chem."},{"key":"10.1016\/j.ejmech.2026.119431_bib47","doi-asserted-by":"crossref","first-page":"27203","DOI":"10.1021\/jacs.6c03429","article-title":"Molecular glues recruiting RNF213 as an E3 ligase for targeted protein degradation: a minimal dibromoacetamide warhead as a recruitment ligand","volume":"148","author":"Jiang","year":"2026","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2026.119431_bib48","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1021\/acs.jmedchem.3c02040","article-title":"Identification of piperazinyl-difluoro-indene derivatives containing pyridyl groups as potent FGFR inhibitors against FGFR mutant tumor: design, synthesis, and biological evaluation","volume":"67","author":"Ding","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119431_bib49","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41557-023-01379-8","article-title":"Proteolysis-targeting chimeras with reduced off-targets","volume":"16","author":"Nguyen","year":"2024","journal-title":"Nat. Chem."},{"key":"10.1016\/j.ejmech.2026.119431_bib50","article-title":"Degron blocking strategy towards improved CRL4CRBN recruiting PROTAC selectivity","volume":"24","author":"Bouguenina","year":"2023","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2026.119431_bib51","doi-asserted-by":"crossref","first-page":"8216","DOI":"10.1039\/D2CS00387B","article-title":"Discovery of Small Molecule Ligands for the von Hippel-Lindau (VHL) E3 Ligase and Their Use as Inhibitors and PROTAC Degraders","volume":"51","author":"Diehl","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2026.119431_bib52","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/s41586-025-09763-9","article-title":"Inhibitors supercharge kinase turnover through native proteolytic circuits","volume":"649","author":"Scholes","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119431_bib53","doi-asserted-by":"crossref","first-page":"16271","DOI":"10.1021\/acs.jmedchem.1c01576","article-title":"Integrative modeling of PROTAC-mediated ternary complexes","volume":"64","author":"Weng","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119431_bib54","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1042\/EBC20170041","article-title":"Molecular recognition of ternary complexes: a new dimension in the structure-guided design of chemical degraders","volume":"61","author":"Hughes","year":"2017","journal-title":"Essays Biochem."},{"key":"10.1016\/j.ejmech.2026.119431_bib55","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1038\/s41467-023-39904-5","article-title":"Affinity and cooperativity modulate ternary complex formation to drive targeted protein degradation","volume":"14","author":"Wurz","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119431_bib56","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1021\/acs.jcim.1c01150","article-title":"Importance of three-body problems and protein-protein interactions in proteolysis-targeting chimera modeling: insights from molecular dynamics simulations","volume":"62","author":"Li","year":"2022","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.119431_bib57","doi-asserted-by":"crossref","first-page":"W296","DOI":"10.1093\/nar\/gky427","article-title":"SWISS-MODEL: homology modelling of protein structures and complexes","volume":"4","author":"Waterhouse","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2026.119431_bib58","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2026.119431_bib59","doi-asserted-by":"crossref","first-page":"7835","DOI":"10.1021\/acs.jcim.5c01063","article-title":"Recent developments in amber biomolecular simulations","volume":"65","author":"Case","year":"2025","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.119431_bib60","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","article-title":"ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB","volume":"11","author":"Maier","year":"2015","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.ejmech.2026.119431_bib61","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jcc.20035","article-title":"Development and testing of a general amber force field","volume":"25","author":"Wang","year":"2004","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2026.119431_bib62","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1063\/1.445869","article-title":"Comparison of simple potential functions for simulating liquid water","volume":"79","author":"Jorgensen","year":"1983","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.ejmech.2026.119431_bib63","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1021\/ct400314y","article-title":"Routine microsecond molecular dynamics simulations with AMBER on GPUs. 2. Explicit solvent particle mesh ewald","volume":"9","author":"Salomon-Ferrer","year":"2013","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.ejmech.2026.119431_bib64","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1021\/ct400341p","article-title":"PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data","volume":"9","author":"Roe","year":"2013","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.ejmech.2026.119431_bib65","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1021\/ct300418h","article-title":"MMPBSA.py: an efficient program for end-state free energy calculations","volume":"8","author":"Miller","year":"2012","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.ejmech.2026.119431_bib66","series-title":"Pymol Molecular Graphics System, Version 2.0","author":"Schr\u00f6dinger","year":"2015"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426008767?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426008767?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:59:03Z","timestamp":1792508343000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426008767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":66,"alternative-id":["S0223523426008767"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119431","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of selective FGFR2\/4 degraders with potent antiproliferative activity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119431","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119431"}}